Sumitomo Mitsui Ds Asset Management Company, LTD Sarepta Therapeutics, Inc. Transaction History

Sumitomo Mitsui Ds Asset Management Company, LTD

$9.15 Billion
Q3 2024

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Jul 19, 2021	SELL	$69.38 - $86.75 $286,678 - $358,451	-4,132 Closed	0 $0
Q1 2021 May 07, 2021	BUY	$72.25 - $168.95 $3,106 - $7,264	43 Added 1.05%	4,132 $307,000
Q4 2020 Feb 02, 2021	SELL	$125.56 - $178.74 $5,399 - $7,685	-43 Reduced 1.04%	4,089 $697,000
Q3 2020 Oct 29, 2020	BUY	$127.12 - $172.34 $1,525 - $2,068	12 Added 0.29%	4,132 $580,000
Q1 2020 Apr 21, 2020	BUY	$82.38 - $131.64 $2,224 - $3,554	27 Added 0.66%	4,120 $403,000
Q4 2019 Jan 24, 2020	BUY	$76.53 - $135.58 $51,198 - $90,703	669 Added 19.54%	4,093 $528,000
Q3 2019 Oct 16, 2019	BUY	$72.81 - $156.91 $249,301 - $537,259	3,424 New	3,424 $257,000

Others Institutions Holding SRPT

# of Institutions

529

Shares Held

84.2M

Call Options Held

2.06M

Put Options Held

1.52M

Black Rock Inc. New York, NY

10.3M
Shares

$1.23 Billion
0.04% of portfolio
Vanguard Group Inc Valley Forge, PA

8.97M
Shares

$1.07 Billion
0.02% of portfolio
Capital International Investors Los Angeles, CA

6.26M
Shares

$745 Million
0.16% of portfolio
Janus Henderson Group PLC London, X0

4.36M
Shares

$519 Million
0.29% of portfolio
State Street Corp Boston, MA

4.27M
Shares

$508 Million
0.02% of portfolio

View Full List

About Sarepta Therapeutics, Inc.

Ticker SRPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,567,904
Market Cap $10.4B
Description
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...

More about SRPT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Sumitomo Mitsui Ds Asset Management Company, LTD, based on Form 13F filings with the SEC.

News

Stay updated on Sumitomo Mitsui Ds Asset Management Company, LTD with notifications on news.

Account